These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 5124632)

  • 1. [Use of cyclophosphane in the treatment of myelofibrosis].
    Klimova NF; Indosova EN
    Probl Gematol Pereliv Krovi; 1971 Jul; 16(7):11-6. PubMed ID: 5124632
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment procedures in myelofibrosis].
    Klimova NF
    Probl Gematol Pereliv Krovi; 1978; 23(11):31-5. PubMed ID: 714890
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose thalidomide in myelofibrosis.
    Weinkove R; Reilly JT; McMullin MF; Curtin NJ; Radia D; Harrison CN
    Haematologica; 2008 Jul; 93(7):1100-1. PubMed ID: 18508796
    [No Abstract]   [Full Text] [Related]  

  • 4. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
    Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
    Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cyclosporin-A on anemia in idiopathic myelofibrosis.
    Falcone A; Musto P; Carotenuto M
    Haematologica; 1998 Jul; 83(7):665-6. PubMed ID: 9718875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose intravenous methylprednisolone in the treatment of idiopathic myelofibrosis.
    Ozsoylu S
    Eur J Haematol; 1988 Mar; 40(3):280. PubMed ID: 3356244
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate.
    Stagno F; Consoli C; Mannino F; Guglielmo P; Giustolisi R
    Eur J Haematol; 2004 Aug; 73(2):147-8. PubMed ID: 15245516
    [No Abstract]   [Full Text] [Related]  

  • 8. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus.
    Paquette RL; Meshkinpour A; Rosen PJ
    Medicine (Baltimore); 1994 May; 73(3):145-52. PubMed ID: 8190037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-25 (OH)2 D3 in idiopathic myelofibrosis: a preliminary report.
    Petrini M; Cecconi N; Ambrogi F; Grassi B
    Haematologica; 1987; 72(6):567-9. PubMed ID: 3126118
    [No Abstract]   [Full Text] [Related]  

  • 10. High dose i.v. MP for idiopathic myelofibrosis: a further case.
    Ozsoylu S
    Eur J Haematol; 1988 Mar; 40(3):282. PubMed ID: 3356246
    [No Abstract]   [Full Text] [Related]  

  • 11. Pyoderma gangrenosum associated with idiopathic myelofibrosis. Case history.
    Sgarabotto D; Vianello F; Valeri P; Tison T; Caenazzo A; Pietrogrande F; Poletti A; Girolami A
    Haematologia (Budap); 1993; 25(4):249-52. PubMed ID: 8157206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.
    Pullarkat V; Bass RD; Gong JZ; Feinstein DI; Brynes RK
    Am J Hematol; 2003 Jan; 72(1):8-12. PubMed ID: 12508261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
    Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
    Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelofibrosis: response to busulfan after hydroxyurea failure.
    Naqvi T; Baumann MA
    Int J Clin Pract; 2002 May; 56(4):312-3. PubMed ID: 12074218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic myelofibrosis associated with dermatomyositis.
    Muslimani A; Ahluwalia MS; Palaparty P; Daw HA
    Am J Hematol; 2006 Jul; 81(7):559-60. PubMed ID: 16755562
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: an ex vivo study.
    Galimberti S; Canestaro M; Ciancia E; Fazzi R; Marasca R; Petrini M
    Leuk Res; 2008 Aug; 32(8):1324-5. PubMed ID: 18192008
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment with valproic acid for myelofibrosis with myeloid metaplasia.
    Inoue Y; Suzuki T; Takimoto M; Irei M; Yoshioka S; Shibuya Y; Kato M; Koike M; Takahashi M
    Ann Hematol; 2005 Nov; 84(12):833-4. PubMed ID: 16132902
    [No Abstract]   [Full Text] [Related]  

  • 18. [Myelobromel in the treatment of patients with idiopathic myelofibrosis during erythremic phase].
    Komiva NF
    Probl Gematol Pereliv Krovi; 1970 Jan; 15(1):50-3. PubMed ID: 5420384
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
    Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y
    Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.
    Huang J; Tefferi A
    Eur J Haematol; 2009 Aug; 83(2):154-5. PubMed ID: 19366369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.